Rachael A. Potter - Gene Therapy Research, Sarepta Therapeutics, Inc.

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 24 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Use of plasmapheresis to lower anti-AAV antibodies in nonhuman primates with pre-existing immunity to AAVrh74

Rachael A. Potter,Ellyn L. Peterson, Grace Cooper Olson,Sarah Lewis, Kyle Cochran,Jerry R. Mendell,Louise R. Rodino-Klapac

MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT（2024）

引用0浏览0WOS引用

AAV-based CRISPR-Cas9 genome editing: Challenges and engineering opportunities

Ami M. Kabadi, Maria Katherine Mejia-Guerra, John D. Graef, Sohrab Z. Khan,Eric M. Walton, Xinzhu Wang,Charles A. Gersbach,Rachael Potter

CURRENT OPINION IN BIOMEDICAL ENGINEERING (2024): 100517

引用0浏览0引用

Systemic γ-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C/R5 mouse model

Young-Eun Seo,Stephen H Baine, Amber N Kempton, Oliver C Rogers,Sarah Lewis, Kaitlin Adegboye, Alex Haile,Danielle A Griffin,Ellyn L Peterson,Eric R Pozsgai,Rachael A Potter,Louise R Rodino-Klapac

Molecular Therapy - Methods & Clinical Development (2023): 284-299

引用4浏览0WOS引用

Evaluating Pharmacology and Efficacy of Delandistrogene Moxeparvovec in Young and Aged DMDmdx Rats

Rachael Potter,Chris Wier,Grace Cooper-Olson, Esther Wheeler,Emily Anderbery,Amber Kempton,Leah Clements, Kaitlin Adegboye,Alex Haile, Ellyn Peterson,Louise Rodino-Klapac

MOLECULAR THERAPY（2023）

引用0浏览0引用

Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy

Jerry R. Mendell,Perry B. Shieh,Craig M. McDonald,Zarife Sahenk,Kelly J. Lehman,Linda P. Lowes,Natalie F. Reash,Megan A. Iammarino,Lindsay N. Alfano, Brenna Sabo,Jeremy D. Woods,Christy L. Skura,

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2023): 1167762-1167762

引用2浏览0WOS引用

Safety and efficacy of pre-treatment with imlifidase prior to AAV-based gene therapy in non-human primates with pre-existing anti-AAVrh74 antibodies

R. Potter,S. Khan, J. Snedeker, K. Adegboye, A. Haile, B. Sayanjali, N. Pukos, K. Cochran, J. Ahner, T. Su, N. Uzcategui,Y. Stenberg,

NEUROMUSCULAR DISORDERS (2023): S101-S101

引用1浏览0引用

P314: Long-term safety and sustained functional benefit in patients with DMD 4 years post-treatment with delandistrogene moxeparvovec: A phase 1/2a study*

Erin O’Rourke,Jerry R. Mendell,Zarife Sahenk,Kelly J. Lehman,Linda P. Lowes,Natalie F. Reash,Megan Iammarino,Lindsay Alfano,Sarah Lewis,Kathleen Church,Richard Shell,Rachael A. Potter,

Genetics in Medicine Openno. 1 (2023): 100342-100342

引用0浏览0引用

Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial

Jerry R Mendell,Zarife Sahenk,Kelly J Lehman,Linda P Lowes,Natalie F Reash,Megan A Iammarino,Lindsay N Alfano,Sarah Lewis,Kathleen Church,Richard Shell,Rachael A Potter,Danielle A Griffin,

Muscle & nerve（2023）

引用2浏览0WOS引用

Expression and function of Four AAV-based constructs for dystrophin restoration in the mdx mouse model of duchenne muscular dystrophy

Rachael A Potter,Danielle A Griffin,Kristin N Heller,Jerry R Mendell,Louise R Rodino-Klapac

Biology open（2023）

引用0浏览0WOS引用

Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged=4 to & lt;8?Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR)

Craig M. Zaidman,Crystal M. Proud,Craig M. Mcdonald,Kelly J. Lehman,Natalie L. Goedeker,Stefanie Mason,Alexander P. Murphy,Maitea Guridi,Shufang Wang,Carol Reid,Eddie Darton,Christoph Wandel,

Annals of neurology（2023）

引用1浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn